Theriva Biologics
TOVX
51 hedge funds and large institutions have $71.6M invested in Theriva Biologics in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
13% more funds holding
Funds holding: 45 → 51 (+6)
2% more capital invested
Capital invested by funds: $70.2M → $71.6M (+$1.37M)
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$1.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$571K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$317K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$275K |
| 5 |
BCM
Bluefin Capital Management
New York
|
+$190K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.11M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$625K |
| 3 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$487K |
| 4 |
Morgan Stanley
New York
|
-$444K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$95K |
TOVX Hedge Fund Activity: Q4 2015 in Review
51 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2015, worth a combined $71.6M — up 2% from $70.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TOVX positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was William Blair & Company, adding an estimated $1.25M. The largest seller was EAM Investors, exiting entirely with an estimated $1.11M sold.
- 51 institutional investors held Theriva Biologics (TOVX) as of Q4 2015, up from 45 in Q3 2015.
- Funds reported $71.6M of Theriva Biologics stock for Q4 2015, up 2% quarter-over-quarter.
- 10 funds opened new Theriva Biologics positions in Q4 2015 and 4 closed out, a net change of +6 holders.
- The largest Theriva Biologics buyer in Q4 2015 was William Blair & Company, an estimated $1.25M added.
- The largest Theriva Biologics seller in Q4 2015 was EAM Investors, an estimated $1.11M sold.
Based on aggregated 13F filings for Q4 2015.